DAY ONE
7:30 am Registration & Light Breakfast
8:25 am Chair’s Opening Remarks
Examining Next-Gen Clinical Models that Better Recapitulate Chronic & Progressive Fibrotic Diseases to Build Translational Confidence in Early Development Candidates
8:30 am Leveraging Human Tissue Models for Discovery & Development: A Novel Approach to Preclinical Development
Synopsis
- Examining human-centric discovery with deep phenotyping and RNA chemistry
- Uncovering ex-vivo human-organ perfusion models for the identification, characterization and validation of late-stage liver disease targets
9:00 am Moving Beyond Acute Models Which Lack the Recapitulation of Human Fibrosis Necessary for Translational Confidence, to Chronis Models of Fibrosis
Synopsis
- Overcoming the lack of preclinical models which do not recapitulate the slow and progressive nature of human fibrosis
- Critically evaluating the predictive power of novel models including patient-derived organoids, 3D tissue engineering platforms, and genetically engineered animal models
9:30 am Developing Advanced Preclinical Models that Better Recapitulate Disease & Patient Heterogeneity & Pathophysiology
Synopsis
- Explore cutting-edge preclinical models that more accurately mimic the complexity and variability of human fibrotic diseases, capturing the nuances of patient heterogeneity and disease pathophysiology
- Uncover how advanced preclinical systems improve the predictive power for clinical outcomes, bridging the gap between early research and human trials with greater fidelity
10:00 am Speed Networking
Synopsis
This informal session provides the perfect opportunity to connect with the industry frontrunners and key opinion leaders focusing on fibrosis across the Lung, Liver, Kidney, Cardiac, Gastrointestinal and Scleroderma Landscapes. Establish meaningful connections to build upon for the rest of the conference and gain exclusive first-hand insights into the latest research and developments driving progression across the cross fibrosis disease field.
10:45 am Morning Break
Examining Non-Invasive Measures of Disease Progression Tracking & Clinical Efficacy with Novel Biomarkers & the Latest Technological Advances in Imaging Technologies
11:00 am Round Table Discussion: Leveraging Non-Invasive Biomarkers for Disease Progression Tracking and Clinical Efficacy
Synopsis
This interactive session gives you the opportunity to be part of the discussion, get ready to share ideas and learn from your peers. Amongst your table’s talking points to consider include:
The Role of Advanced Imaging Technologies in Biomarker Development
What are the limitations and challenges of
integrating these imaging technologies into clinical practice?
Share examples where advanced imaging
has significantly impacted fibrosis research
Standardization and Validation of Non-Invasive Biomarkers
What are the critical steps in the
standardization and validation process of
non-invasive biomarkers for fibrosis?
How can we ensure reproducibility and
consistency across different laboratories
and clinical settings?
Translational Applications and Clinical Implementation
How can non-invasive biomarkers be
effectively translated from research to
clinical applications?
What are the potential impacts of these
biomarkers on patient care and treatment
outcomes in fibrosis?
Mitigating the Heterogenous & Complex Nature of Fibrotic Diseases with Innovative Therapeutic Strategies
11:30 am Leveraging Non-Invasive Imaging & Mass Spectrometry Technologies to Quantify Fibrosis
Synopsis
- Explore how prequalified and validated antibodies are used to visualize ECM proteins and fibrillar collagen through immunoblotting and immunohistochemistry
- Discover the use of second harmonic generation (SHG) microscopy and fluorescence lifetime imaging microscopy (FLIM) for quantifying fibrotic lesions in living rodents
- Learn about the application of LC-MS/MS protocols to quantify distinct forms of collagen, crucial for understanding the mechanisms of fibrosis
12:00 pm Examining the Molecular Profile of Responders & Non-Responders to Segment Heterogenous Disease Populations
Synopsis
- Examining the molecular and cellular changes in patients who respond to therapy and secondary changes that occur beyond the immediate impact of the drug to reveal critical insights into disease mechanisms and therapeutic efficacy
- Exploring retrospective analysis to uncover predictive biomarkers and how these can enhance confidence in therapeutic decisions and patient stratification improving patient outcomes
- Analysis of molecular changes in non-responders compared to responders to uncover insights into potential treatment gaps and the need for additional or alternative therapies
12:30 pm Lunch Break
1:30 pm Leveraging Patient Data & Clinical Endpoints for Reverse Translation: Uncovering Efficacious Targets in Fibrotic Diseases
Synopsis
- Examine how large-scale patient data sets can inform early-stage drug discovery and how to leverage these patient data sets to identify potential causative targets
- Highlighting the connection between functional endpoints and anti-fibrotic effects to understand which functional clinical endpoints are good surrogates for antifibrotic efficacy and targets with a higher probability of being associated with worse disease severity
2:00 pm Dynamic Fibrogenesis in Human Precision Cut Tissue Slices: An Unrivalled Preclinical Platform for Testing Novel Therapies
Synopsis
- Human precision cut tissue slices (PCS) retain the cellular complexity and architecture of the native tissue in culture.
- Utilizing dynamic models of tissue inflammation and fibrogenesis in lung, liver, kidney, heart and skin.
- Application of PCS for drug testing, target engagement and assessment of efficacy.
2:30 pm Integrating Therapeutic Platform with Biomarkers & Genetic Analysis for Novel Targets that Mitigate the Heterogenous Nature of Fibrotic Diseases
Synopsis
- Exploring the unique dual action of AM1476’s and its potential addresses the heterogeneous nature of systemic sclerosis and other fibrotic indications
- Investigating AnaMar’s integration of their therapeutic platform with biomarkers and genetic analysis to enhance the precision and efficacy of AM1476
- Using novel genetic marker approaches using a gene signature to identify responders to treatment
3:00 pm Poster Session
Synopsis
Immerse yourself in an engaging session in a relaxed atmosphere that encourages meaningful conversations and discussions. Explore a range of exciting poster presentations and showcase your own research and developments in the Inflammasome therapeutics space. Don’t miss out on the chance to connect, learn, and present. Get ready to be impressed!
Exploring Target Product Profile & Expansion Strategies to Shape Future Asset Prioritization
4:00 pm Shaping the Future of Antifibrotic Therapeutics with Exploration of Expansion Opportunities & Key Considerations
Synopsis
This session will explore and evaluate emerging trends, identify innovative approaches to differentiate products and strategic insights on how to advance antifibrotic drug development and patient care across a broad spectrum of diseases. Examine the driving factors behind progress and how best to capitalize on these to explore your future expansion strategies.
4:30 pm Examining Target Product Profile: From Signalling Cascades to Cell Types & Immunomodulatory Proteins – What is the Best Target & Most Effective Modality
Synopsis
- Discuss the most promising signalling cascades, cell types, and immunomodulatory proteins that can be targeted to effectively combat fibrosis
- Analyse different therapeutic modalities, including small molecules, biologics, and gene therapies, to identify the most effective and precise approach to targeting fibrosis with as few side effects as possible
5:00 pm Panel & Audience Discussion: Collaborative Strategies for Advancing Antifibrotic Drug Development Across Diverse Disease Indications
Synopsis
This panel discussion gathers experts from across the various disease indications to discuss what is needed to collectively advance antifibrotic drug development across the broad spectrum of diseases.
Expect coverage of:
- With an increase recognition of the complexity and heterogeneity of fibrotic diseases, will combination therapies be necessary to secure clinical efficacy above the current standards of care?
- What is the true bottleneck halting progression of antifibrotic therapeutics through the clinical and to patients?
- Do we need to focus on detecting higher risk patients for earlier diagnosis and earlier intervention to prevent late-stage fibrosis?
- Where should we be directing future research efforts?